Introduction
Genetic clotting disorders, or inherited coagulation disorders, are medical conditions marked by abnormalities in the blood clotting process. These disorders can lead to excessive bleeding or abnormal clot formation, posing significant challenges to affected individuals. Understanding genetic clotting disorders' causes, symptoms, and management is crucial for patients and healthcare professionals.
What Are Some Inherited Clotting Disorders?
A certain condition, a genetic disorder, can increase the likelihood of children developing blood clots or blockages in their veins or arteries. This condition, inherited from parents, includes:
Factor V(5) Leiden: Factor V(5) Leiden is a common genetic disorder associated with blood clot formation. Individuals with this condition usually inherit one affected gene and one normal gene from their parents. Factor V is a protein crucial for blood clot formation. In those with factor V Leiden, the body struggles to regulate factor V, leading to excessive blood clotting.
Children with one affected gene have a significantly higher risk of blood clots than those without factor V Leiden. Most children with factor V Leiden will not experience blood clots during childhood or adolescence. Still, certain factors, such as serious medical conditions, central lines, undiagnosed autoimmune diseases, or birth control, can elevate the risk.
For instance, while only one out of 50,000 healthy teenagers might develop a blood clot, a teenage girl on birth control faces a three-fold increased risk. If they also have factor V Leiden, their risk becomes substantially higher.
To illustrate, a 16-year-old girl with factor V Leiden on birth control has a risk of about one out of 1,500 of developing a blood clot. Factor V Leiden affects various population groups differently:
-
Families with Middle Eastern ancestry (Arab countries, Turkey, and Armenia) have the highest rates, around ten percent.
-
Families with Southern European ancestry (Greece and Italy) have rates around five percent.
-
Families with Central and Northern European ancestry have rates ranging from two to five percent.
-
The factor V Leiden mutation occurs in about two to ten percent of Caucasians.
-
People without white ancestors (African, Asian, Native American, or Pacific Islanders) do not carry the factor V Leiden gene.
The Prothrombin Mutation: The prothrombin mutation is the second most common genetic disorder related to blood clotting. Nearly all children with this mutation inherit one affected gene from their parents, although having both genes affected is rare. Prothrombin is vital for normal blood clotting, but children with this mutation have excess prothrombin, leading to increased blood clot formation.
Children with one affected gene have a two- to three-fold higher risk of developing a blood clot than those without the mutation. However, most children with this mutation will not experience blood clots during childhood or adolescence unless they have certain medical conditions, a central line, an undiagnosed autoimmune disease, or use birth control.
The prothrombin mutation affects about two to three percent of children with white ancestry, and children of mixed ancestry can also be affected. Having both genes affected is rarer, occurring in about one out of 10,000 children.
Protein C and Protein S Deficiency: Protein C and protein S collaborate to prevent blood clotting in the body. If a child lacks sufficient levels of either protein, they face an increased risk of blood clots. A child's risk of blood clotting rises significantly, by ten to 20 times, if they inherit a deficiency in protein C or protein S from their parents. However, most children with these deficiencies will not experience blood clots during childhood or adolescence.
Protein C Deficiency:
-
Affects individuals of all races.
-
Inherited protein C deficiency occurs in about one out of 1,000 people.
-
Treatment typically involves Ceprotin, a blood-derived product that replaces the missing protein C.
Protein S Deficiency:
-
Affects individuals of all races.
-
Inherited protein S deficiency occurs in about one out of 5,000 people.
-
Treatment usually involves plasma or blood thinners.
Severe Protein C and Protein S Deficiency: This severe condition, affecting less than one out of a million people, often results in babies being born with blood clots, causing brain damage and blindness. Identification occurs after birth due to large purple patches on the skin, indicating blood clots within the skin.
Non-Genetic Protein C and Protein S Deficiency: Although uncommon, children with liver disease or vitamin K deficiency can also experience protein C or protein S deficiency.
Antithrombin Deficiency:
-
Antithrombin is a natural blood clot prevention protein.
-
Insufficient levels of antithrombin can lead to an increased risk of blood clots, more so than protein C or protein S deficiency, often occurring during childhood or adolescence.
Who Gets Affected?
-
Antithrombin deficiency affects approximately one out of 20,000 to 50,000 people.
-
The risk of blood clotting depends on the individual's antithrombin levels.
Elevated Homocysteine
Homocysteine, an amino acid found naturally in the body, can reach elevated levels due to certain genetic disorders inherited from parents. High homocysteine levels can enhance the risk of blood clots or blockages in arteries and veins. While extremely high levels (above 100, with normal levels below 12) are rare and often associated with various medical issues, they are typically identified shortly after birth or within the first year of life.
More commonly, high homocysteine levels can result from a poor diet lacking in B vitamins (B6, B12, and folic acid) or from conditions affecting blood or intestinal health, which hinder the absorption of these vitamins. Children with impaired kidney function may also experience elevated homocysteine levels.
Elevated Lipoprotein (a)
Lipoprotein (a) is a type of natural fat molecule in the body, similar to cholesterol. Its exact role in the body needs to be clarified. Like cholesterol levels, lipoprotein (a) levels can be high in certain families. Elevated lipoprotein (a) can double the risk of blood clots.
Unfortunately, there is no reliable method to lower lipoprotein (a). Unlike cholesterol, it is not influenced by diet or exercise. High doses of niacin, a type of vitamin, may sometimes reduce lipoprotein (a) levels, but niacin can have side effects and may not work for everyone. Children who have experienced blood clots due to high lipoprotein (a) levels typically require treatment with blood thinners, which they may need to continue for an extended period.
Antiphospholipid Antibody Syndrome (APLA or APLAS)
Antiphospholipid antibody syndrome (APLAS), unlike many other conditions that cause blood clots, is not something someone is born with. It is an autoimmune disorder where the immune system mistakenly attacks healthy body parts. While APLAS can run in families, it has no specific gene like some other conditions.
The exact cause of APLAS and how common it is among children has yet to be fully understood, but it is not considered rare. It is believed that APLAS might create tiny holes in the cells lining blood vessels, which can lead to blood clots forming more easily. APLAS is more often seen in teenage girls and young women, and it can cause complications during pregnancy.
When a blood clot occurs in an otherwise healthy child, it is important to check for APLAS through special blood tests. However, interpreting these test results can be complex, so it is best to have an expert in blood clotting conditions explain them.
Conclusion
Genetic clotting disorders disrupt the body's natural clotting process, potentially causing excessive bleeding or abnormal clot formation. These conditions, including factor V(5) Leiden, prothrombin mutation, protein C and protein S deficiency, antithrombin deficiency, elevated homocysteine, elevated lipoprotein (a), and antiphospholipid antibody syndrome, highlight the diverse genetic and environmental factors influencing clotting. Management strategies tailored to individual needs are crucial for mitigating risks and enhancing patient care.
